Fierce Pharma
JANUARY 9, 2024
Pfizer knows it had a bad year in 2023. Speaking to reporters at the 2024 J.P. | Pfizer knows it had a bad year in 2023. Speaking to reporters at the 2024 J.P. Morgan Healthcare Conference on Monday, the company’s CEO, Albert Bourla, spoke bluntly about the hits the company took, and he acknowledged the underperformance of certain key launches.
European Pharmaceutical Review
JANUARY 9, 2024
Revolutionising quality control In the backdrop of stringent quality standards and regulatory demands inherent to pharmaceutical manufacturing, the addition of AI technologies introduce a paradigm shift. This article highlights the manifold applications of AI, particularly cutting-edge image recognition and computer vision systems, which profoundly impact quality control.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JANUARY 9, 2024
Two successful phase 3 trials put Astellas’ monoclonal antibody zolbetuximab on track to become the first approved therapy to treat one of the hottest targets in oncology—tumors that are claudin (C | Two successful phase 3 trials put Astellas’ monoclonal antibody zolbetuximab on track to become the first approved therapy to treat one of the hottest targets in oncology—tumors that are claudin (CLDN) positive.
PharmExec
JANUARY 9, 2024
Merck has acquired Harpoon Therapeutics with its clinical stage T-cell engager, whereas Johnson & Johnson acquired Ambrx Biopharma with its expertise in next generation antibody drug conjugates and targeted oncologic therapies.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
JANUARY 9, 2024
San Francisco—Despite its recent $43 billion acquisition of Seagen, Pfizer is still on the lookout for deals centered on antibody-drug conjugates | Despite its recent $43 billion acquisition of Seagen, Pfizer is still on the lookout for deals centered on antibody-drug conjugates, Pfizer’s newly minted chief oncology officer Chris Boshoff, Ph.D., said in an interview.
MedCity News
JANUARY 9, 2024
XRHealth’s $6 million in funding was led by Asabys Partners and included participation from NOVA Prime Fund. The company will use the funding to support its recent merger with Amelia Virtual Care.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
JANUARY 9, 2024
Though GSK divested much of its oncology assets to Novartis in 2015, the company has built it back through a internal R&D and business development deals. GSK Senior Vice President, Global Head of Oncology, R&D Hesham Abdullah explained the company’s evolving cancer strategy in an interview during the J.P. Morgan Healthcare Conference in San Francisco.
Copyright Clearance Center
JANUARY 9, 2024
January 9, 2024 – Danvers, Mass. – CCC , a pioneer in voluntary collective licensing with the mission of advancing copyright, accelerating knowledge, and powering innovation, announces that RightFind XML , the company’s scientific article discovery solution, was chosen as the Bio-IT World 2023 Best in Show award honoree at its World Conference & Expo Europe in London.
MedCity News
JANUARY 9, 2024
Walgreens has agreed to pay Humana $360 million to settle a drug pricing dispute that has spanned nearly five years. The payout is roughly half of what Walgreens was originally ordered to pay when the issue was first resolved last year.
European Pharmaceutical Review
JANUARY 9, 2024
Chiesi Farmaceutici (Chiesi Group) and Oak Hill Bio, a clinical-stage neonatology and rare disease therapeutics company, have agreed to collaborate and develop , manufacture , and commercialise an investigational drug candidate for treating pre-term birth complications. OHB-607 is a human IGF-1 replacement of insulin-like growth factor-1 (IGF-1), a key driver of foetal growth and development, and its binding protein, IGFBP-3 for prevention of bronchopulmonary dysplasia in preterm infants, Chiesi
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
JANUARY 9, 2024
Jill DeGraff, B.well Connected Health’s senior vice president of regulatory, believes the ONC’s new HTI-1 rule is a step in the right direction that will improve data exchange for providers, health tech vendors and patients. She applauded the rule for preserving TEFCA as a voluntary framework and for establishing FHIR-based interoperability as the industry’s de facto standard.
European Pharmaceutical Review
JANUARY 9, 2024
Pfizer’s oral poly ADP-ribose polymerase (PARP) inhibitor TALZENNA ® (talazoparib), in combination with XTANDI ® (enzalutamide) has been approved for prostate cancer by the European Commission (EC). TALZENNA the first and only PARP inhibitor licensed in the EU for use with XTANDI for patients with mCRPC, with or without gene mutations” The treatment is indicated for adults with metastatic castration-resistant prostate cancer (mCRPC) in individuals where chemotherapy is not clinically indi
pharmaphorum
JANUARY 9, 2024
Manufacturing problems have scuppered Astellas’ chances of approval in the US this month for zolbetuximab, currently leading the field among Claudin 18.2-targeted drug candidates for cancer.
MedCity News
JANUARY 9, 2024
The healthcare industry stands to benefit greatly from stronger payer and provider partnerships. As the industry works to tear down the barriers that currently exist to bringing these stakeholders together, there are mutually beneficial opportunities that should be considered now.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
JANUARY 9, 2024
Day 1 of JPM24 ended with no news on a rumoured takeover of Cytokinetics by Novartis, but Boston Scientific confirmed a $3.7bn bid for medtech specialist Axonics.
MedCity News
JANUARY 9, 2024
The real-time, automated nature of green lighting offers precise control without the setbacks or manual efforts inherent to conventional gold carding programs.
pharmaphorum
JANUARY 9, 2024
Amazon has launched an initiative with Omada Health at JPM that makes it easier for patients to discover and enrol in digital health benefit programmes
Pharmaceutical Commerce
JANUARY 9, 2024
Review article explores the latest developments surrounding expression and purification strategies.
pharmaphorum
JANUARY 9, 2024
Novo Nordisk Foundation has put $25m of funding into CARB-X, an initiative that aims to tackle antimicrobial resistance (AMR).
PharmExec
JANUARY 9, 2024
The Healthcare Businesswomen’s Association will honor the recipient at an event later this year in New York City.
PharmaTimes
JANUARY 9, 2024
Both aim to advance the use of AI-powered cell analysis for cancer, stem cell and cell therapies
PharmExec
JANUARY 9, 2024
Industry stakeholders must come together to make meaningful changes to reimbursement and establish comprehensive policies that support essential healthcare providers.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmaTimes
JANUARY 9, 2024
The fertilised eggs could cultivate tumours for imaging within seven days
pharmaphorum
JANUARY 9, 2024
JPM: GSK announces $1.4bn deal to buy asthma biotech Aiolos Phil.
Clarify Health
JANUARY 9, 2024
Hospitals today are complex businesses facing the dual challenges of growing revenue while maintaining operational efficiency. Provider organizations can use predictive analytics to fuel strategic growth, identify savings opportunities, and drive greater efficiency for staff and patients. Predictive analytics empower healthcare organizations to strategically expand by leveraging data to forecast future trends and identify potential areas for efficient growth.
PharmaTech
JANUARY 9, 2024
Bradley Grobler, Vice President of Sales, Pharma & Biopharma Europe, describes how Actylis meets global demands for (bio)pharmaceutical development and manufacturing programs during CPhI 2023.
Spotio
JANUARY 9, 2024
Have you worked in the solar industry for long? Then you know that very few customers purchase solar panels on the spot. Instead, they ask for proposals so they can compare offers. So, one of the best ways to close deals in this field is to produce quality proposals, then distribute them at lightning fast speeds. Enter: solar proposal software. In this article, we’ll explain what solar proposal software is, why it’s so beneficial to sellers like you, how to choose between the many op
PharmaTech
JANUARY 9, 2024
Ascendia Pharmaceuticals CEO, Jim Huang, describes how new opportunities in formulation development complement the company’s previous work in developing novel nanotechnologies to support biopharmaceutical development.
Pharmaceutical Commerce
JANUARY 9, 2024
Astellas said it will work closely with the FDA and a third-party manufacturer to develop a timeline that will quickly resolve feedback from the complete response letter to a Biologics License Application for zolbetuximab.
PharmaTech
JANUARY 9, 2024
Robert Bloder, Chief Business Officer, Ascendia Pharmaceuticals, highlights traits that a (bio)pharmaceutical company look for when identifying a CDMO to support drug development and manufacturing programs.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
345 
Let's personalize your content